AKEBIA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
AKEBIA THERAPEUTICS, INC. (AKBA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $12.43 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $12.43M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$8.31M, a 137.25% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$44.96M, a 198.67% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$31.69M, a 206.39% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$177.26M, a 1495.20% decline from fiscal 2016.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $12.71M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$13.69M.
- AKEBIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$65.35M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 85 month |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | $12.43M 10-Q · filed 2018-05-09 | $4.13M derived: sum of 2 quarters · filed 2018-05-09 | -$40.83M derived: sum of 3 quarters · filed 2018-05-09 | -$72.52M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-12-31 | -$8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$53.27M derived: sum of 2 quarters · filed 2018-03-12 | -$84.96M derived: sum of 3 quarters · filed 2018-03-12 | -$177.26M 10-K · filed 2018-03-12 | |||
| 2017-09-30 | -$44.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$76.65M derived: sum of 2 quarters · filed 2017-11-08 | -$168.95M 10-Q · filed 2017-11-08 | -$146.65M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-06-30 | -$31.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$123.99M 10-Q · filed 2017-08-08 | -$101.69M derived: sum of 3 quarters · filed 2018-05-09 | -$56.12M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2017-03-31 | -$92.30M 10-Q · filed 2018-05-09 | -$70.00M derived: sum of 2 quarters · filed 2018-05-09 | -$24.43M derived: sum of 3 quarters · filed 2018-05-09 | $5.36M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | $22.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $67.87M derived: sum of 2 quarters · filed 2018-03-12 | $97.66M derived: sum of 3 quarters · filed 2018-03-12 | $12.71M 10-K · filed 2018-03-12 | |||
| 2016-09-30 | $45.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $75.35M derived: sum of 2 quarters · filed 2017-11-08 | -$9.60M 10-Q · filed 2017-11-08 | -$7.96M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-06-30 | $29.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$55.17M 10-Q · filed 2017-08-08 | -$53.53M derived: sum of 3 quarters · filed 2018-03-12 | -$67.98M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-03-31 | -$84.95M 10-Q · filed 2017-05-09 | -$83.32M derived: sum of 2 quarters · filed 2018-03-12 | -$97.77M derived: sum of 3 quarters · filed 2018-03-12 | -$102.05M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2015-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$12.82M derived: sum of 2 quarters · filed 2018-03-12 | -$17.09M derived: sum of 3 quarters · filed 2018-03-12 | -$13.69M 10-K · filed 2018-03-12 | |||
| 2015-09-30 | -$14.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$18.73M derived: sum of 2 quarters · filed 2016-11-09 | -$15.33M 10-Q · filed 2016-11-09 | -$22.96M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2015-06-30 | -$4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$871.00K 10-Q · filed 2016-08-08 | -$8.51M derived: sum of 3 quarters · filed 2017-03-06 | -$48.51M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2015-03-31 | $3.40M 10-Q · filed 2016-05-05 | -$4.23M derived: sum of 2 quarters · filed 2017-03-06 | -$44.23M derived: sum of 3 quarters · filed 2017-03-06 | -$67.31M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2014-12-31 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$47.63M derived: sum of 2 quarters · filed 2017-03-06 | -$70.71M derived: sum of 3 quarters · filed 2017-03-06 | -$65.35M 10-K · filed 2017-03-06 | |||
| 2014-09-30 | -$40.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$63.07M derived: sum of 2 quarters · filed 2015-11-09 | -$57.72M 10-Q · filed 2015-11-09 | -$55.98M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-06-30 | -$23.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | -$17.72M 10-Q · filed 2015-08-11 | -$17.72M 10-Q · filed 2014-08-11 | -$15.98M derived: sum of 3 quarters · filed 2016-03-14 | |||
| 2014-03-31 | $5.36M 10-Q · filed 2015-05-11 | $5.36M 10-Q · filed 2014-05-12 | $7.09M derived: sum of 2 quarters · filed 2016-03-14 | -$6.32M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$11.43M 10-K · filed 2016-03-14 | |||||
| 2013-09-30 | -$13.16M 10-Q · filed 2014-11-10 | ||||||
| 2012-12-31 | $1.37M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |